Report overview
Recombinant activated factor VII (rFVIIa) binds to exposed tissue factor at the place of tissue and vascular injury. Thrombin generated by this process activates platelets and the coagulation cascade.
This report contains market size and forecasts of Recombinant Human Coagulation VIIa in global, including the following market information:
Global Recombinant Human Coagulation VIIa Market Revenue, 2018-2023, 2023-2030, ($ millions)
Global Recombinant Human Coagulation VIIa Market Sales, 2018-2023, 2023-2030, (K Units)
Global top five Recombinant Human Coagulation VIIa companies in 2022 (%)
The global Recombinant Human Coagulation VIIa market was valued at 1166.6 million in 2022 and is projected to reach US$ 1488.4 million by 2030, at a CAGR of 3.5% during the forecast period 2023-2030.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2030.
Prefilled Syringe Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Recombinant Human Coagulation VIIa include Novo Nordisk, LFB SA HEMA Biologics, AryoGen Pharmed and GENERIUM, etc. In 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Recombinant Human Coagulation VIIa manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Recombinant Human Coagulation VIIa Market, by Type, 2018-2023, 2023-2030 ($ Millions) & (K Units)
Global Recombinant Human Coagulation VIIa Market Segment Percentages, by Type, 2022 (%)
Prefilled Syringe
Vial
Global Recombinant Human Coagulation VIIa Market, by Application, 2018-2023, 2023-2030 ($ Millions) & (K Units)
Global Recombinant Human Coagulation VIIa Market Segment Percentages, by Application, 2022 (%)
Congenital Hemophilia
Acquired Hemophilia
Others
Global Recombinant Human Coagulation VIIa Market, By Region and Country, 2018-2023, 2023-2030 ($ Millions) & (K Units)
Global Recombinant Human Coagulation VIIa Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Recombinant Human Coagulation VIIa revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Recombinant Human Coagulation VIIa revenues share in global market, 2022 (%)
Key companies Recombinant Human Coagulation VIIa sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Recombinant Human Coagulation VIIa sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novo Nordisk
LFB SA HEMA Biologics
AryoGen Pharmed
GENERIUM
